ADAP - Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022

• SPEARHEAD-1 trial using afami-cel for the treatment of patients with synovial sarcoma and MRCLS met its primary endpoint with an objective response rate of 34%.
• A BLA filing for afami-cel for the treatment of patients with synovial sarcoma and MRCLS is expected in Q4 of 2022.
• The success of the SPEARHEAD-1 study established proof of concept that Adaptimmune's SPEAR T-cell technology platform can be used to go after other types of solid tumors.
• Adaptimmune has a huge deal in place with Genentech in which it could earn up to $3 billion in potential milestone payments should all the programs being advanced go well.

For further details see: